Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Precigen Inc 20374 Seneca Meadows Parkway Germantown MD 20876 USA

www.precigen.com P: 301-556-9900

Description:

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 343,508
Enterprise Value, $K 335,928
Shares Outstanding, K 248,919
Annual Sales, $ 6,230 K
Annual Net Income, $ -95,900 K
Last Quarter Sales, $ 1,230 K
Last Quarter Net Income, $ -33,060 K
EBIT, $ -88,930 K
EBITDA, $ -73,620 K
60-Month Beta 1.77
% of Insider Shareholders 41.70%
% of Institutional Shareholders 33.51%
Float, K 145,120
% Float 58.30%
Short Volume Ratio 0.46

Growth:

1-Year Return 13.11%
3-Year Return -80.06%
5-Year Return -70.45%
5-Year Revenue Growth -96.12%
5-Year Earnings Growth 74.45%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.09 on 03/19/24
Latest Earnings Date 05/08/24 [--]
Earnings Per Share ttm -0.35
EPS Growth vs. Prev Qtr -12.50%
EPS Growth vs. Prev Year -378.57%
Annual Dividend Yield 0.00%
Most Recent Dividend 0.162 on 06/09/15
Dividend Payout Ratio 0.00%

PGEN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -55.48%
Return-on-Assets % -43.25%
Profit Margin % -1,539.33%
Debt/Equity 0.00
Price/Sales 57.58
Price/Cash Flow N/A
Price/Book 2.94
Book Value/Share 0.48
Interest Coverage -204.02

PGEN Dividends

Date Value
06/09/15 $0.1620
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar